Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 6/20 | 0.56 |
| ▸ | JAK3 | P52333 | 10/20 | 0.53 |
| ▸ | JAK1 | P23458 | 8/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.49 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 4/20 | 0.47 |
| ▸ | BTK | Q06187 | 4/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PAK4 | O96013 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1474404 | 0.86 | JAK3 (0.72) | SYKJAK3JAK1ALKEGFR | |
| SCHEMBL1198388 | 0.83 | ALK (0.49) | SYKJAK3JAK1ALKCDK19 | |
| SCHEMBL1475290 | 0.82 | JAK3 (0.62) | SYKJAK3JAK1ALKEGFR | |
| SCHEMBL1474027 | 0.79 | JAK3 (0.49) | SYKJAK3JAK1ALKEGFR | |
| SCHEMBL1474401 | 0.79 | JAK3 (0.49) | SYKJAK3JAK1ALKEGFR | |
| SCHEMBL30413372 | 0.79 | JAK3 (0.49) | SYKJAK3JAK1ALKEGFR | |
| SCHEMBL3109617 | 0.79 | BRD4 (0.55) | SYKJAK3JAK1JAK2FLT3 | |
| SCHEMBL1477193 | 0.79 | JAK1 (0.50) | SYKJAK3JAK1ALKJAK2 | |
| SCHEMBL1474025 | 0.79 | JAK3 (0.48) | SYKJAK3JAK1ALKEGFR | |
| SCHEMBL1197711 | 0.78 | MAPT (0.55) | SYKJAK3JAK1ALKCDK19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | claimed |
| WO-2008118823-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | WO | claimed |
| US-8299087-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110027856-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-7834024-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008118823-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | SYK 62/4885JAK3 1/4885JAK1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.